Sort
48,018 grants matching “immunotherapy”
Role of Novel Cytokine Secretoglobin (SCGB) 3A2 in Lung
$651,304Shioko Kimura · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)
$651,186Vera P Krymskaya · University Of Pennsylvania · R01 · FY2016 · HL
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$651,173Nirav Thosani · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · CA
MS4A7 in tumor resistance to immunotherapy
$651,124Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Role of DeltaNp63 alpha and TIP60 in SCC progression and chemoresistance
$651,120Madhavi P Kadakia · Wright State University · R01 · FY2024 · CA
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$651,026Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2021 · CA
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2019 · AI
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2018 · AI
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2017 · AI
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2016 · AI
Mutagenic chain reaction-facilitated immunotherapy
$651,000Stephen M Hedrick · University Of California, San Diego · R01 · FY2020 · AI
Mayo Comprehensive Cancer Center Grant
$650,997Robert B. Diasio · Mayo Clinic Rochester · P30 · FY2016 · CA
MACROPHAGE-CENTRIC PROGNOSTIC BIOMARKERS FOR CHECKPOINT BLOCKADE IMMUNOTHERAPY IN MELANOMA
$650,845University Of Alabama At Birmingham · · FY2025 · Defense Health Agency
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
$650,815Tyler J. Curiel · University Of Texas Hlth Science Center · R01 · FY2017 · CA
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
$650,786Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2019 · CA
Developing a novel combination immunotherapy for triple-negative breast cancer
$650,749Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2025 · CA
Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies
$650,719Anirban Maitra · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Efficacy - Characterization of Potential Antigens for Immunization Against Colon
$650,687University Of Oklahoma Hlth Sciences Ctr · N01 · FY2012 · CA
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy
$650,671Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA
IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma
$650,649Ekaterina Koltsova · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Steady states and cellular transitions associated with carcinogenesis and tumorprogression
$650,589James R. Heath · Institute For Systems Biology · U01 · FY2019 · CA
DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy
$650,458Karl T Kelsey · Brown University · R01 · FY2022 · CA
Lung Cancer Immunotherapy using new generation of TCR-engineered CD4 + T cells
$650,450Rongfu Wang · University Of Southern California · R01 · FY2025 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$650,424Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2022 · CA
Biochemical and cellular analysis of regulatory T cells reactive to a natural self antigen
$650,415Erin June Adams · University Of Chicago · R01 · FY2020 · AI